| Substanz | Ab welchem Lebensjahr für die Therapie der Psoriasis vulgaris zugelassen (Stand 10/2022) |
|---|---|
| Adalimumab | Ab dem 4. Lebensjahr |
| Etanercept | Ab dem 6. Lebensjahr |
| Ustekinumab | Ab dem 6. Lebensjahr |
| Ixekizumab | Ab dem 6. Lebensjahr |
| Secukinumab | Ab dem 6. Lebensjahr |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.